Senior Senators Seek Details On Government Audits Of 340B Entities
This article was originally published in The Pink Sheet Daily
Executive Summary
Top Republicans on two Senate health committees are joined by House members in seeking answers on an HHS review of entities receiving 340B drug discounts, including the process and consequences of audits and decertification.
You may also be interested in...
Hatch, Alexander Expected To Helm Health Panels In Senate
Orrin Hatch, the supplement industry’s chief congressional ally and veteran of major pharmaceutical legislative initiatives, is in line to head the Finance Committee with Republican control of the Senate. The HELP Committee – with jurisdiction over public health – could be Lamar Alexander’s first chair opportunity.
Hatch, Alexander Expected To Helm Health Panels In Senate
Orrin Hatch, the supplement industry’s chief congressional ally and veteran of major pharmaceutical legislative initiatives, is in line to head the Finance Committee with Republican control of the Senate. The HELP Committee – with jurisdiction over public health – could be Lamar Alexander’s first chair opportunity.
Sens. Hatch, Alexander Expected To Helm Health Panels In Senate
Orrin Hatch, the veteran of major pharmaceutical legislative initiatives, is in line to head the Finance Committee with the change to Republican control of the Senate. The Health, Education, Labor and Pensions Committee – with jurisdiction over biomedical R&D and public health – will be headed by Lamar Alexander, in his first opportunity to chair a committee.